CDK7 and CDK9 Inhibition Interferes with Transcription, Translation and Stemness, and Induces Cytotoxicity in GBM Irrespective of Temozolomide Sensitivity

Scientists examined the effect of a CDK7 inhibitor, THZ1, and multiple CDK9 inhibitors on glioblastoma cell lines, patient-derived temozolomide-resistant and responsive primary tumor cells and glioma stem cells.